Amr Shafik Saad

Amr Shafik Saad

Auto-generated profile, based on publicly available information

Amr Shafik Saad

Department of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Translational Research
Verified
Journal Article
Closed access
MKMarwa M. Kamel
Marwa M. Kamel
marwa matbolimarwa matboli
marwa matboli
MSMaha Sallam
Maha Sallam
IMIman F. Montasser
Iman F. Montasser
ASAmr S. Saad
Amr S. Saad
AEAhmed H.F. El-Tawdi
Ahmed H.F. El-Tawdi

6 October 2015 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
RSRana Sayed
Rana Sayed
ASAmr S Saad
Amr S Saad
LWLamia M El Wakeel
Lamia M El Wakeel
EEEngi Elkholy
Engi Elkholy
OBOsama Badary
Osama Badary
Metformin Addition to Chemotherapy in Stage IV Non-Small Cell Lung Cancer: an Open Label Randomized Controlled Study Metformin;lung cancer;survival;mTOR;non-small cell; Purpose: To evaluate effects of metformin on clinical outcome of non-diabetic patients with stage IV NSCLC. Materials and Methods: A prospective, randomized, open-label, controlled pilot study was conducted on patients with stage IV NSCLC with an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2, excluding patients with diabetes and lactic acidosis. Thirty chemo-$na\ddot{i}ve$, non-diabetic patients with stage IV NSCLC were enrolled. Fifteen patients received intravenous gemcitabine/cisplatin regimen alone (arm B) while fifteen patients received the same regimen plus daily oral metformin 500mg (arm A). The effect of metformin on chemotherapy-response rates, survival, and adverse events in these patients was evaluated. Results: Objective response rate (ORR) and median overall survival (OS) in arms A and B were 46.7% versus 13.3% respectively, p=0.109 and 12 months versus 6.5 months, respectively, p=0.119. Median progression free survival (PFS) in arms A and B was 5.5 months versus 5 months, p=0.062. No significant increase in toxicity was observed in arm A versus arm B. Percentage of patients who experienced nausea was significantly lower in arm A versus arm B, at 26.7% versus 66.7% respectively, p=0.028. Conclusions: Metformin administration reduced occurrence of chemotherapy induced-nausea. Non-statistically significant improvements in the ORR or OS were observed. Metformin had no effect on PFS.


27 October 2016 in Oncology Research
Verified
Journal Article
Open access
MEManal El-Hamamsy
Manal El-Hamamsy
HEHesham Elwakil
Hesham Elwakil
ASAmr S. Saad
Amr S. Saad
MSMay A. Shawki
May A. Shawki
Statins have been reported to have a potential radiosensitizing effect that has not been evaluated in clinical trials. The aim of this study was to evaluate the efficacy and safety of simvastatin in addition to whole-brain radiation therapy (WBRT) in patients with brain metastases (BM). A prospective randomized, controlled, open-label pilot study was conducted on 50 Egyptian patients with BM who were randomly assigned to receive 30-Gy WBRT (control group: 25 patients) or 30 Gy WBRT + simvastatin 80 mg/day for the WBRT period (simvastatin group: 25 patients). The primary outcome was radiological response at 4 weeks after WBRT. Secondary outcomes were 1-year progression-free survival (PFS), 1-year overall survival (OS), and health-related quality of life (HRQL) that was assessed using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) and its brain module (BN-20), at baseline, after WBRT, and 4 weeks after WBRT. The addition of simvastatin was tolerated. Twenty-one patients were not evaluated for radiological response because of death (n = 16), noncompliance to follow-up (n = 4), and clinical deterioration (n = 1). Response rates were 60% and 78.6% (p = 0.427), 1-year PFS rates were 5.2% and 17.7% (p = 0.392), and 1-year OS rates were 12% and 8% (p = 0.880) for the control group and simvastatin group, respectively. Nonsignificant differences were found between the two arms regarding HRQL scales. The addition of simvastatin 80 mg/day did not improve the clinical outcomes of patients with BM receiving WBRT.

31 July 2013 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
RARasha M Abd El Atti
Rasha M Abd El Atti
HGHoda H Abou Gabal
Hoda H Abou Gabal
WOWesam M Osman
Wesam M Osman
ASAmr S Saad
Amr S Saad
The histological grade is the gold standard for the evaluation of prognosis of astrocytic tumors. Nevertheless, morphologic criteria are not always accurate prognostic indicators.

1 January 2017 in Journal of Cancer Research and Therapeutics
Verified
Journal Article
Closed access
PDF file
MSMay Ahmed Shawki
May Ahmed Shawki
ASAmr Shafik Saad
Amr Shafik Saad
RGRamy R Ghali
Ramy R Ghali
Background: The use of cisplatin (Cis) versus carboplatin (Carb) in the treatment of advanced nonsmall cell lung cancer (NSCLC) is controversial. The aim of the study was to compare the safety and efficacy of Cis versus Carb in squamous NSCLC. Patients and Methods: A prospective, randomized, controlled, open-label study was conducted on advanced squamous NSCLC patients who were randomly assigned to receive Cis (40 mg/m 2 [day 1 and day 8]) or Carb (area under the curve = 5 [day 1]) combined with gemcitabine [Gem] (1000 mg/m 2 [day 1 and day 8]) of a 3-week schedule for six cycles. Study objectives were a radiological response after three cycles and six cycles, 1-year progression-free survival (PFS), 1-year overall survival (OS), and quality of life (QOL) assessment using functional assessment of cancer therapy-lung at baseline, after three cycles, and after six cycles. Statistical Analysis: Statistical analysis was done using Statistical Package for Social Science version 15. A P < 0.05 was considered statistically significant. Results: Seventy-one patients were enrolled (Gem/Cis group [n = 36], Gem/Carb group [n = 35]). Response rates were comparable in both arms. Nonsignificant differences were found regarding 1-year PFS (P = 0.308) and 1-year OS (P = 0.929) between the two groups. Neutropenia was significantly higher in Gem/Carb group, while vomiting and ototoxicity were significantly higher in Gem/Cis group. The effect on QOL was similar in both groups. Conclusion: Cis and Carb have similar efficacy, tolerability, and effect on QOL and both can be used as a first-line treatment of squamous NSCLC.